Fundraising FoxForte Biosciences
NASDAQ: FBRXSherman Oaks, US · Founded 2017 · Delaware corporation · 1 known investors
Find your way into Forte Biosciences
Sign up to see every warm intro you have to Forte Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Forte Biosciences team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, an anti-CD122 monoclonal antibody intended to treat autoimmune diseases including celiac disease, vitiligo, alopecia areata, and type 1 diabetes by modulating immune cell activity.
Founders & leadership
Investors · 1
Funding
SEC filings, press & company announcements$25.2M disclosed across 2 of 3 rounds · 2018–2026
- Undisclosed amountpublic offeringApr 2026Source ↗
▶$19.4MraisedJun 2020 · 19 investors · BiotechnologyRule 506(b)
- Antony RileyExecutive Officer
- Paul A. Wagner, Ph.D.Executive Officer, Director
- Offering amount
- $20M
- Amount sold
- $19.4M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5.8MraisedDec 2018 · 12 investors · BiotechnologyRule 506(b)
- Tuan HuynhDirector
- Lawrence EichenfieldDirector
- Paul WagnerExecutive Officer, Director
- Offering amount
- $10.7M
- Amount sold
- $5.8M
- First sale
- Nov 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Frequently asked questions
- What does Forte Biosciences do?
- Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, an anti-CD122 monoclonal antibody intended to treat autoimmune diseases including celiac disease, vitiligo, alopecia areata, and type 1 diabetes by modulating immune cell activity.
- Who are Forte Biosciences's investors?
- Forte Biosciences's investors include OrbiMed.
- How much funding has Forte Biosciences raised?
- Forte Biosciences has disclosed $25.2M raised across 2 of its 3 known rounds.
- Where is Forte Biosciences headquartered?
- Forte Biosciences is headquartered in Sherman Oaks, US.